The marginalisation of tribals in the last few decades has been enormous. Tribals have lost out in agriculture, and their forests also stand depleted, writes KD Singh In 2006, the Prime Minister described the Maoist threat as “the single biggest internal security challenge ever faced by the country” and suggested development in insurgency-affected regions as the key remedy. In 2009, the Union Government announced a new nationwide initiative, the ‘Integrated Action...

Over 2000 impoverished Burmese asylum-seekers from across India, camping on the streets of Delhi pleading for refugee status were dealt a double whammy. On Tuesday afternoon, even as a delegation of Burmese met UN officials to sort out their problems, they were forced out of their temporary shelter in Vasant Kunj by police, dumped into buses and rickshaws and told to find their way home. To make matters worse, their...

While India faces an acute shortage of trained medical manpower, as many as 1,333 doctors migrated to foreign shores over the last one year. During the same period, the previous year - from April 1, 2010 to March 31, 2011 - 1,157 doctors had migrated in search of employment, and between 2009 and 2010, 1,458 doctors went abroad. This latest revelation by Union health minister Ghulam Nabi Azad on Friday comes just...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...